Seryna G Anderson, LPN | |
475 Sam Webb Loop, Noble, LA 71462-2493 | |
(318) 947-2181 | |
Not Available |
Full Name | Seryna G Anderson |
---|---|
Gender | Female |
Speciality | Licensed Vocational Nurse |
Location | 475 Sam Webb Loop, Noble, Louisiana |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013591999 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
164X00000X | Licensed Vocational Nurse | 30001087 (Louisiana) | Primary |
Mailing Address | Practice Location Address |
---|---|
Seryna G Anderson, LPN 475 Sam Webb Loop, Noble, LA 71462-2493 Ph: (318) 947-2181 | Seryna G Anderson, LPN 475 Sam Webb Loop, Noble, LA 71462-2493 Ph: (318) 947-2181 |
News Archive
If the website malfunctions in October and November were infuriating to supporters of health care reform, the continuing parade of delays that followed it have simply been depressing. They have contributed to the impression that the Obama administration is desperately trying to keep the new system from spinning out of control, countering the good news that 1.2 million people have signed up for insurance through the federal and state exchanges. ... Having cracked once on this subject, the White House will be pushed to do so more forcefully by the law's critics when the policies take effect next month. This should be the last concession (David Firestone, 12/23).
Many gene mutations that cause neurological disorders have been identified. For example, in a rare neurological disorder such as Huntington's disease, an autosomal dominant mutation through expansion of CAG (cytosine-adenine-guanine) triplet repeats in the gene coding for the Huntingtin protein results in abnormal protein production.
Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.
The format of the original Hamilton Rating Scale for Depression (HAM-D) was unstructured: only general instructions were provided for rating individual items.
› Verified 3 days ago